Insider Transactions in Q3 2021 at Exelixis, Inc. (EXEL)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,177
-1.72%
|
$143,540
$20.63 P/Share
|
|
Sep 30
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
28,950
+6.47%
|
-
|
|
Sep 30
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
5,416
-1.75%
|
$108,320
$20.63 P/Share
|
|
Sep 30
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
28,950
+8.54%
|
-
|
|
Sep 30
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,593
-1.15%
|
$151,860
$20.63 P/Share
|
|
Sep 30
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
28,950
+4.21%
|
-
|
|
Sep 30
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,573
-2.02%
|
$171,460
$20.63 P/Share
|
|
Sep 30
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
32,567
+7.13%
|
-
|
|
Sep 21
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
55,057
-12.33%
|
$1,101,140
$20.33 P/Share
|
|
Sep 21
2021
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+16.77%
|
$270,000
$3.66 P/Share
|
|
Sep 16
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
25,000
-8.17%
|
$500,000
$20.36 P/Share
|
|
Sep 16
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.55%
|
$25,000
$1.7 P/Share
|
|
Sep 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
47,500
-10.87%
|
$950,000
$20.46 P/Share
|
|
Sep 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,500
+9.8%
|
$285,000
$6.21 P/Share
|
|
Aug 16
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
55,000
-12.37%
|
$990,000
$18.44 P/Share
|
|
Aug 16
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+11.01%
|
$55,000
$1.9 P/Share
|
|
Jul 26
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+5.49%
|
$160,000
$4.2 P/Share
|
|
Jul 21
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+5.12%
|
$140,000
$4.2 P/Share
|
|
Jul 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
60,000
-13.35%
|
$1,020,000
$17.47 P/Share
|
|
Jul 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+11.78%
|
$60,000
$1.9 P/Share
|
|
Jul 06
2021
|
Charles Cohen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+14.29%
|
$320,000
$4.72 P/Share
|